Transactions
CBCC Global Research recapitalized by Edgewater Capital Partners
May. 2025
Client: CBCC Global Research is a multi-national, science-driven, full-service contract research organization (“CRO”) providing end-to-end clinical development services across Phase I to Phase IV trials. The Company specializes in innovator drugs, biosimilars, and complex generics across core therapeutic areas, including oncology, CNS, ophthalmology, and metabolic disorders.
Role: Edgemont Partners acted as exclusive financial advisor to CBCC Global Research in its recapitalization by Edgewater Capital Partners.
Location: Bakersfield, CA
Sector: Pharmaceutical Services
Lead Banker: Andrew Karlin
recapitalized by
